Most frequent questions and answers
The purpose of the ENABLE COST Action is to support the healthcare professionals and empower patients in detecting and managing non-adherence. Due to an ageing society, there is a steady increase in chronic diseases and multi-morbidity in Europe. This requires a multidisciplinary response, which often involves lifestyle changes combined with lifetime medication use. Technological advances (e.g. smart pillboxes, digital inhalers, tracking devices, e-injection pens, e-Health, big data) have significant potential to support these activities.
ENABLE aims to create a multidisciplinary network of relevant stakeholders that work collaboratively towards economically viable implementation of medication adherence enhancing technologies across different European healthcare systems.
ENABLE has four working groups:
- WG 1 – Current practices and unmet needs
- WG 2 – Adherence enhancing technologies
- WG 3 – Sustainable implementation of adherence enhancing technologies
- WG 4 – Communication and Dissemination
Yes, it is possible in theory, although it is preferable for the organisation of meetings that participants are members of one working group. After discussion with the working group leaders, participants are welcome to visit other groups meetings and participate in discussions.
ENABLE welcomes specialists with expertise on medical and pharmaceutical practice and sciences, nursing, engineering, health psychology, communication, implementation science, health economics and policy. The ENABLE Action plans also to involve also essential stakeholders that can impact the implementation of adherence enhancing interventions immediately: patient associations, informal care associations and regulators (registration authorities, payers and health insurance policy makers). Naturally, other main participants are the engineers that develop these technologies, mostly working in SMEs. Lastly, experts with specific expertise in e.g. communication and dissemination on a European level, such as participants involved in patient advocacy, will be asked to join the ENABLE Action.
Travel fees to meetings, training schools and scientific stays can be fully covered for a large number of participants and, on very specific occasions, fees to participate to conferences can be covered as well. COST actions do not fund for personnel. The only specific case where COST actions do fund for the work achieved by a participant is in the case of Short Term Scientific Missions (STSMs).
ShortTerm Scientific Missions (STSMs) allow participants to perform a collaborative stay at a partner institution or laboratory in another COST country a concept of particular interest to young scientists. STSMs can vary from one week to three months and up to six months for Early Stage Researchers. The average contribution for a mission is a fixed grant based on the applicant’s budget request and the decision from the relevant assessment committee. It will normally not exceed EUR 2,500 (EUR 3500 for Early Stage Researchers).
More info about applications in the COST Vademecum, section 8, https://www.cost.eu/uploads/2021/04/Vademecum-28-April-2021.pdf.